4.67

0.43% -0.010

Cytek Biosciences Inc (CTKB)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$4.66

Aprire:

$4.69

Volume 24 ore:

25,307

Relative Volume:

0.02

Capitalizzazione di mercato:

$607.02M

Reddito:

$204.17M

Utile/perdita netta:

$-74.00M

Rapporto P/E:

-8.0866

EPS:

-0.5775

Flusso di cassa netto:

$-12.84M

1 W Prestazione:

-1.07%

1M Prestazione:

+1.53%

6M Prestazione:

+4.74%

1 anno Prestazione:

+15.71%

Intervallo 1D:

$4.665

$4.6936

Intervallo di 1 settimana:

$4.57

$4.92

Portata 52W:

$3.28

$6.18

Cytek Biosciences Inc Stock (CTKB) Company Profile

Nome

Cytek Biosciences Inc

Settore

Healthcare (1083)

Industria

Medical Devices (140)

Telefono

(877) 922-9835

Indirizzo

47215 LAKEVIEW BOULEVARD, FREMONT

Dipendente

702

Cinguettio

Prossima data di guadagno

2026-08-05

Ultimi documenti SEC

CTKB's Discussions on Twitter

Compare CTKB vs ABT, SYK, MDT, BSX, EW

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
CTKB Cytek Biosciences Inc	4.67	610.92M	204.17M	-74.00M	-12.84M	-0.5775
ABT Abbott Laboratories	114.59	198.01B	46.59B	5.41B	7.38B	3.0938
SYK Stryker Corp	330.78	130.41B	25.27B	3.34B	4.57B	8.6334
MDT Medtronic Plc	92.17	120.48B	36.36B	4.84B	5.43B	3.7261
BSX Boston Scientific Corp	49.67	75.37B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	89.47	53.19B	6.30B	1.07B	1.09B	1.8406

Cytek Biosciences Inc Stock (CTKB) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-12-02	Ripresa	Morgan Stanley	Equal-Weight
2025-05-09	Downgrade	TD Cowen	Buy → Hold
2025-01-31	Downgrade	Goldman	Buy → Sell
2023-12-14	Iniziato	Stephens	Overweight
2023-07-19	Iniziato	Raymond James	Mkt Perform
2022-01-06	Ripresa	Piper Sandler	Overweight

Mostra tutto

Cytek Biosciences Inc Borsa (CTKB) Ultime notizie

Aug 20, 2026

Cytek Biosciences CFO William D. McCombe Executes RSU Vesting and Tax Withholding Transactions - Kalkine Media

Aug 20, 2026

Cytek Biosciences Director Glenn P. Muir Converts 3,086 RSUs to Common Stock on August 18, 2026 - Kalkine Media

Aug 20, 2026

Cytek Biosciences (CTKB) CEO gets 120K shares, surrenders some for taxes - Stock Titan

Aug 20, 2026

Cytek Biosciences (NASDAQ: CTKB) director gains 3,086 no-cost shares - Stock Titan

Aug 20, 2026

Cytek Biosciences (CTKB) director now holds 28,499 shares - Stock Titan

Aug 20, 2026

Cytek Biosciences (CTKB) CTO gets 33,270 shares, surrenders some for taxes - Stock Titan

Aug 20, 2026

Cytek (CTKB) Quarterly Figures: EPS Prints Above Forecast in the Latest Session; Stock Move: Shares Finish 0.96% HigherEstimate Dispersion - Vinanet

Aug 20, 2026

Aug 17, 2026

Cytek Biosciences Balances Growth With Profit Pressures - TipRanks

Aug 17, 2026

Cytek (CTKB) Q2 2026 Earnings Call Transcript - AOL.com

Aug 17, 2026

Aug 12, 2026

Cytek Biosciences (CTKB) awards 241,416 RSUs and 127,118 options to top lawyer - Stock Titan

Aug 12, 2026

Aug 11, 2026

Cytek Biosciences: Recurring Revenue Reaches 35% Of Sales As Installed Base Approaches 4,000 Instruments - Pulse 2.0

Aug 11, 2026

Cytek Biosciences launches Aurora Evo system to drive high-throughput research and small particle detection - Traders Union

Aug 11, 2026

Promising Penny Stocks To Consider In August 2026 - simplywall.st

Aug 11, 2026

Aug 10, 2026

Cytek Biosciences (NASDAQ:CTKB) Trading 8.5% HigherShould You Buy? - MarketBeat

Aug 10, 2026

Aug 08, 2026

Cytek Biosciences, Inc. (8EQ.MU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada

Aug 08, 2026

Aug 07, 2026

Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (ZBH), Cytek Biosciences (CTKB) and Sight Sciences (SGHT) - The Globe and Mail

Aug 07, 2026

Aug 06, 2026